Articulo
Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis
Autor
Kanevsky, Diego
Elgart, Jorge Federico
Zerga, Marta
Glancszpigel, Mariana
Morisset, Pierre
Institución
Resumen
The aim of the study was to estimate the cost-effectiveness of VenG in the treatment of first-line unfit CLL patients in Argentina. XXVII Congress of the European Hematology Association (Viena, 9 al 17 de junio de 2022) Centro de Endocrinología Experimental y Aplicada